Mo Khan News Today

Ghoul morning, america. Its our most spooktacular halloween yet. Weve hung with the pope, olivia pope, honeymooned with hollywood royalty, went gaga for the royal baby and were frozen with delight. Think youve seen it all . You aint seen nothing yet. Get ready for the biggest, scariest, most hilarious halloween in times scare ever only on gma. From abc news, live in times scare, friday, october 30th this is ghoul morning, america. Times scare. I love that. We do good morning, america. Yes, we ar...

HVIVO plc, a leading CRO in infectious disease trials, announces strong financial results and operational achievements for 2023, setting the stage for continued growth.

Companies are delivering world-beating progress in many sectors - but they are battling for recognition.

Companies are delivering world-beating progress in many sectors - but they are battling for recognition.

Company says it will begin paying dividends

HVIVO plc, the world leader in infectious disease testing, has reported double-digit revenue growth and improved EBITDA margins and cash for 2023. The company expects to pay an annual dividend and has set a new revenue target of £100 million by 2028. The growing orderbook and high revenue visibility indicate a strong market position.

Pharmaceutical services firm Hvivo has signed a £6.3m (€7.3m) contract with a biotechnology client.

HVIVO plc £6.3m HRV Contract Signed with Biotechnology Client

American investors have good reason to feel festive. US markets have soared during 2023, fed by better-than-expected economic figures and a rebound in titans such as Amazon, Apple and Meta.

Drug-testing specialist hVivo was one of the top tips for 2023 from The Daily Mail's Midas column, but the paper still reckons there's further to go despite the stock doubling in price over the year.